A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases

Despite the success of current biological therapeutics for rheumatoid arthritis, these therapies, targeting individual cytokines or pathways, produce beneficial responses in only about half of patients. Therefore, better therapeutics are needed. IL-6 and IL-17A are proinflammatory cytokines in many...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Biol Chem
Egile Nagusiak: Lyman, Michael, Lieuw, Vincent, Richardson, Robyn, Timmer, Anjuli, Stewart, Christine, Granger, Steve, Woods, Richard, Silacci, Michela, Grabulovski, Dragan, Newman, Roland
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Biochemistry and Molecular Biology 2018
Gaiak:
Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005441/
https://ncbi.nlm.nih.gov/pubmed/29678878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M117.818559
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak